Adult Glioblastoma Clinical Trial
Official title:
A Phase II Evaluation With Correlative Studies Of Fenretinide (NSC 374551-4HPR) As A Single Agent In The Treatment Of Adult Patients With Recurrent Glioblastoma Multiforme
This randomized phase II trial is studying how well neoadjuvant and adjuvant fenretinide works compared to adjuvant fenretinide alone in treating patients who are undergoing surgical resection for recurrent glioblastoma multiforme. Chemotherapy drugs, such as fenretinide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed. Giving chemotherapy after surgery may kill any remaining tumor cells. It is not yet known whether neoadjuvant and adjuvant fenretinide is more effective than adjuvant fenretinide alone
Status | Terminated |
Enrollment | 42 |
Est. completion date | |
Est. primary completion date | March 2005 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed glioblastoma multiforme after initial tumor resection - Radiologically evident recurrent tumor after prior radiotherapy OR after treatment for no more than 2 prior relapses - Enhancing or nonenhancing recurrent disease by MRI - No progressive symptoms requiring urgent surgery - Performance status - Karnofsky 70-100% - More than 8 weeks - Absolute granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - PT/PTT no greater than upper limit of normal - SGPT no greater than 2.5 times normal - Alkaline phosphatase no greater than 2.5 times normal - Bilirubin less than 1.5 mg/dL - BUN no greater than 1.5 times normal - Creatinine no greater than 1.5 times normal - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception during and for 2 months after study participation - Amylase and lipase normal - No active infection - No other disease that would obscure toxicity or dangerously alter drug metabolism - No other concurrent serious medical illness - Not at risk from any study treatment delays - Able to swallow fenretinide capsules - Recovered from all prior chemotherapy - Approximately 2 weeks since prior vincristine - Approximately 6 weeks since prior nitrosoureas - Approximately 3 weeks since prior procarbazine - See Disease Characteristics - At least 2 weeks since prior radiotherapy - See Disease Characteristics - At least 1 week since prior vitamin A - At least 1 week since prior isotretinoin (Accutane®) - No concurrent vitamin A during and for 2 weeks after study participation - No concurrent antioxidants (e.g., ascorbic acid or vitamin E) |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | M D Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) | Up to 6 months | No | |
Primary | Plasma and tissue concentrations of fenretinide and its metabolite, 4-MPR using high-performance liquid chromatography (HPLC) assay | At baseline, and at 1, 7, 14, and 21 days | No | |
Primary | Tumor apoptotic index after fenretinide treatment by immunohistochemistry | At the time of surgery | No | |
Primary | Correlation between tumor apoptotic index with serum and tissue fenretinide levels | At the time of surgery | No | |
Primary | Correlation of time to progression with drug levels and apoptotic index | Up to 2 years | No | |
Secondary | Fenretinide effects on retinol, RBP, retinoid receptor levels and IGF-1 | Up to 21 days (course 1 and 4) | No | |
Secondary | Fenretinide activity using magnetic resonance spectroscopy (MRS) | At the time of surgery | No | |
Secondary | Radiological response | Up to 2 years | No | |
Secondary | Overall survival | Up to 2 years | No | |
Secondary | Unexpected toxicity associated with fenretinide as assessed by CTC version 3.0 | Up to 2 years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02530502 -
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 1 | |
Withdrawn |
NCT02194452 -
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
|
N/A | |
Completed |
NCT00238303 -
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00049387 -
Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
|
Phase 1 | |
Completed |
NCT02227901 -
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT02015819 -
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
|
Phase 1 | |
Active, not recruiting |
NCT02179086 -
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 2 | |
Recruiting |
NCT04573140 -
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
|
Phase 1 | |
Active, not recruiting |
NCT00823797 -
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
|
Phase 2 | |
Completed |
NCT00045565 -
Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Completed |
NCT01977677 -
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
|
Phase 1/Phase 2 | |
Completed |
NCT01648348 -
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00004262 -
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT01996527 -
3T MRI Biomarkers of Glioma Treatment Response
|
Early Phase 1 | |
Terminated |
NCT01575275 -
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT01119599 -
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Terminated |
NCT01103375 -
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
|
Phase 1 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00459381 -
Pazopanib in Treating Patients With Recurrent Glioblastoma
|
Phase 2 | |
Completed |
NCT00316849 -
Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 1 |